• Je něco špatně v tomto záznamu ?

Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens

Kalina T, Vaskova M, Mejstrikova E, Madzo J, Trka J, Stary J, Hrusak O.

. 2005 ; 5 (1) : 38.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc07520271

Grantová podpora
NE7430 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Aberrant expression of myeloid antigens (MyAgs) on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon, although its regulating mechanisms are unclear. MyAgs in ALL are interpreted e.g. as hallmarks of early differentiation stage and/or lineage indecisiveness. Granulocytic marker CD66c -- Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is aberrantly expressed on ALL with strong correlation to genotype (negative in TEL/AML1 and MLL/AF4, positive in BCR/ABL and hyperdiploid cases). METHODS: In a cohort of 365 consecutively diagnosed Czech B-precursor ALL patients, we analyze distribution of MyAg+ cases and mutual relationship among CD13, CD15, CD33, CD65 and CD66c. The most frequent MyAg (CD66c) is studied further regarding its stability from diagnosis to relapse, prognostic significance and regulation of surface expression. For the latter, flow cytometry, Western blot and quantitative RT-PCR on sorted cells is used. RESULTS: We show CD66c is expressed in 43% patients, which is more frequent than other MyAgs studied. In addition, CD66c expression negatively correlates with CD13 (p < 0.0001), CD33 (p = 0.002) and/or CD65 (p = 0.029). Our data show that different myeloid antigens often differ in biological importance, which may be obscured by combining them into "MyAg positive ALL". We show that unlike other MyAgs, CD66c expression is not shifted from the onset of ALL to relapse (n = 39, time to relapse 0.3-5.3 years). Although opposite has previously been suggested, we show that CEACAM6 transcription is invariably followed by surface expression (by quantitative RT-PCR on sorted cells) and that malignant cells containing CD66c in cytoplasm without surface expression are not found by flow cytometry nor by Western blot in vivo. We report no prognostic significance of CD66c, globally or separately in genotype subsets of B-precursor ALL, nor an association with known risk factors (n = 254). CONCLUSION: In contrast to general notion we show that different MyAgs in lymphoblastic leukemia represent different biological circumstances. We chose the most frequent and tightly genotype-associated MyAg CD66c to show its stabile expression in patients from diagnosis to relapse, which differs from what is known on the other MyAgs. Surface expression of CD66c is regulated at the gene transcription level, in contrast to previous reports.

000      
00000naa 2200000 a 4500
001      
bmc07520271
003      
CZ-PrNML
005      
20130417132928.0
008      
090330s2005 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kalina, Tomáš, $d 1975 říjen 11.- $7 xx0060125
245    10
$a Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens / $c Kalina T, Vaskova M, Mejstrikova E, Madzo J, Trka J, Stary J, Hrusak O.
314    __
$a Department of Immunology, Charles University 2nd Medical School, Prague, Czech Republic. tomas.kalina@lfmotol.cuni.cz
520    9_
$a BACKGROUND: Aberrant expression of myeloid antigens (MyAgs) on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon, although its regulating mechanisms are unclear. MyAgs in ALL are interpreted e.g. as hallmarks of early differentiation stage and/or lineage indecisiveness. Granulocytic marker CD66c -- Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is aberrantly expressed on ALL with strong correlation to genotype (negative in TEL/AML1 and MLL/AF4, positive in BCR/ABL and hyperdiploid cases). METHODS: In a cohort of 365 consecutively diagnosed Czech B-precursor ALL patients, we analyze distribution of MyAg+ cases and mutual relationship among CD13, CD15, CD33, CD65 and CD66c. The most frequent MyAg (CD66c) is studied further regarding its stability from diagnosis to relapse, prognostic significance and regulation of surface expression. For the latter, flow cytometry, Western blot and quantitative RT-PCR on sorted cells is used. RESULTS: We show CD66c is expressed in 43% patients, which is more frequent than other MyAgs studied. In addition, CD66c expression negatively correlates with CD13 (p < 0.0001), CD33 (p = 0.002) and/or CD65 (p = 0.029). Our data show that different myeloid antigens often differ in biological importance, which may be obscured by combining them into "MyAg positive ALL". We show that unlike other MyAgs, CD66c expression is not shifted from the onset of ALL to relapse (n = 39, time to relapse 0.3-5.3 years). Although opposite has previously been suggested, we show that CEACAM6 transcription is invariably followed by surface expression (by quantitative RT-PCR on sorted cells) and that malignant cells containing CD66c in cytoplasm without surface expression are not found by flow cytometry nor by Western blot in vivo. We report no prognostic significance of CD66c, globally or separately in genotype subsets of B-precursor ALL, nor an association with known risk factors (n = 254). CONCLUSION: In contrast to general notion we show that different MyAgs in lymphoblastic leukemia represent different biological circumstances. We chose the most frequent and tightly genotype-associated MyAg CD66c to show its stabile expression in patients from diagnosis to relapse, which differs from what is known on the other MyAgs. Surface expression of CD66c is regulated at the gene transcription level, in contrast to previous reports.
650    _2
$a CD antigeny $x biosyntéza $7 D015703
650    _2
$a antigeny CD13 $x biosyntéza $7 D018826
650    _2
$a antigen Lewis X $x biosyntéza $7 D016256
650    _2
$a mladiství $7 D000293
650    _2
$a antigeny diferenciační myelomonocytární $x biosyntéza $7 D015214
650    _2
$a western blotting $7 D015153
650    _2
$a molekuly buněčné adheze $x biosyntéza $7 D015815
650    _2
$a buněčná membrána $x metabolismus $7 D002462
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dítě $7 D002648
650    _2
$a kohortové studie $7 D015331
650    _2
$a cytoplazma $x metabolismus $7 D003593
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genotyp $7 D005838
650    _2
$a glykosylace $7 D006031
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a kojenec $7 D007223
650    _2
$a akutní lymfatická leukemie $x metabolismus $7 D054198
650    _2
$a prognóza $7 D011379
650    _2
$a RNA $x metabolismus $7 D012313
650    _2
$a recidiva $7 D012008
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a časové faktory $7 D013997
650    _2
$a genetická transkripce $7 D014158
650    _2
$a financování organizované $7 D005381
651    _2
$a Česká republika $7 D018153
700    1_
$a Vášková, Martina, $d 1979- $7 xx0106094
700    1_
$a Mejstříková, Ester, $d 1977- $7 xx0105223
700    1_
$a Madžo, Jozef, $d 1976- $7 xx0037668
700    1_
$a Trka, Jan, $d 1966- $7 xx0036261
700    1_
$a Starý, Jan, $d 1952- $7 jn19990009994
700    1_
$a Hrušák, Ondřej, $d 1965- $7 xx0036691
773    0_
$w MED00008171 $t BMC cancer $g Roč. 5, č. 1 (2005), s. 38 $x 1471-2407
910    __
$a ABA008 $b x $y 9
990    __
$a 20090325104238 $b ABA008
991    __
$a 20130417133207 $b ABA008
999    __
$a ok $b bmc $g 638074 $s 490872
BAS    __
$a 3
BMC    __
$a 2005 $b 5 $c 1 $d 38 $i 1471-2407 $m BMC cancer $x MED00008171
GRA    __
$a NE7430 $p MZ0
LZP    __
$a 2009-B1/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...